Geovax Labs Inc. (GOVX) Issues H1 2024 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
GeoVax Provides First Half 2024 Business Update
July 9, 2024 9:10 AM EDTAward of BARDA Project NextGen contract represents a significant milestone event;
total value of award to GeoVax and its CRO partner total approximately $367-388 million
BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVaxs
multi-antigen vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19
Progress across pipeline with planned data readouts in multiple trials expected during H2 2024
ATLANTA, GA - (NewMediaWire) - July 09, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today provided a business... More
